Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin

• Published in: Molecular cancer therapeutics Vol. 5; no. 12; pp. 2977 - 2990
• Main Authors: Tsai, Wilson S, Yeow, Wen-Shuz, Chua, Alex, Reddy, Rishindra M, Nguyen, Duc M, Schrump, David S, Nguyen, Dao M
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.12.2006
• Subjects: Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apo2L/TRAIL; Apoptosis - drug effects; caspase; Caspases - metabolism; Cell Line, Tumor; cisplatin; Cisplatin - administration & dosage; Cisplatin - pharmacology; Death Domain Receptor Signaling Adaptor Proteins - biosynthesis; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - pathology; Humans; Isoenzymes - metabolism; mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Proto-Oncogene Proteins c-bcl-2 - biosynthesis; TNF-Related Apoptosis-Inducing Ligand - administration & dosage; TNF-Related Apoptosis-Inducing Ligand - pharmacology

Although expressing adequate levels of functional tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptors DR4/DR5, significant proportion of cancer cells exhibit resistance to the cytotoxic effect of this ligand. Exposure of Apo2L/TRAIL-refractory cancer cells to cytotoxic chemothe...